Truist analyst Richard Newitter raised the firm’s price target on Stryker (SYK) to $380 from $370 and keeps a Hold rating on the shares. The company posted a “solid” Q3 organic revenue beat and boasts one of the better growth profiles in large cap MedTech, with several new launch areas set to build momentum into Q4 and FY25, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SYK:
- Stryker price target raised to $420 from $380 at Piper Sandler
- Stryker price target raised to $370 from $366 at UBS
- Stryker price target raised to $400 from $360 at Canaccord
- Stryker price target raised to $394 from $383 at BTIG
- Stryker price target raised to $400 from $386 at RBC Capital
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
